CO2023000016A2 - Proteínas enpp1 o enpp3 solubles y sus usos - Google Patents
Proteínas enpp1 o enpp3 solubles y sus usosInfo
- Publication number
- CO2023000016A2 CO2023000016A2 CONC2023/0000016A CO2023000016A CO2023000016A2 CO 2023000016 A2 CO2023000016 A2 CO 2023000016A2 CO 2023000016 A CO2023000016 A CO 2023000016A CO 2023000016 A2 CO2023000016 A2 CO 2023000016A2
- Authority
- CO
- Colombia
- Prior art keywords
- enpp3
- enpp1
- proteins
- deficiency
- compositions
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 101000812677 Homo sapiens Nucleotide pyrophosphatase Proteins 0.000 abstract 3
- 101000897042 Homo sapiens Nucleotide pyrophosphatase Proteins 0.000 abstract 3
- 102100021969 Nucleotide pyrophosphatase Human genes 0.000 abstract 3
- 102100039306 Nucleotide pyrophosphatase Human genes 0.000 abstract 3
- 230000007812 deficiency Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000034970 Heterotopic Ossification Diseases 0.000 abstract 1
- 230000002308 calcification Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04001—Phosphodiesterase I (3.1.4.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
- C12Y306/01009—Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063036833P | 2020-06-09 | 2020-06-09 | |
| PCT/US2021/036494 WO2021252549A1 (en) | 2020-06-09 | 2021-06-08 | Soluble enpp1 or enpp3 proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023000016A2 true CO2023000016A2 (es) | 2023-02-16 |
Family
ID=76731053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0000016A CO2023000016A2 (es) | 2020-06-09 | 2023-01-03 | Proteínas enpp1 o enpp3 solubles y sus usos |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230313158A1 (https=) |
| EP (1) | EP4162036A1 (https=) |
| JP (1) | JP2023529892A (https=) |
| KR (1) | KR20230042263A (https=) |
| CN (1) | CN116157145A (https=) |
| AR (1) | AR122578A1 (https=) |
| AU (1) | AU2021286502A1 (https=) |
| BR (1) | BR112022024958A2 (https=) |
| CA (1) | CA3181983A1 (https=) |
| CO (1) | CO2023000016A2 (https=) |
| IL (1) | IL298853A (https=) |
| MX (1) | MX2022015772A (https=) |
| TW (1) | TW202214849A (https=) |
| WO (1) | WO2021252549A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3246877A1 (en) * | 2022-03-30 | 2023-10-05 | Yale University | METHOD AND COMPOSITIONS FOR THE TREATMENT, ALLEVIATION AND/OR PREVENTION OF DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS (DISH) |
| WO2023196820A2 (en) * | 2022-04-04 | 2023-10-12 | Inozyme Pharma, Inc. | Treatment of enpp1 deficiency and abcc6 deficiency |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
| GB8918616D0 (en) | 1989-08-15 | 1989-09-27 | Univ Glasgow | Herpes simplex virus type 1 mutant |
| US20020164782A1 (en) | 1999-02-10 | 2002-11-07 | Gregory Richard J. | Adenovirus vectors for gene therapy |
| US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
| ES2124303T3 (es) | 1992-03-25 | 1999-02-01 | Depomed Inc | Formas de dosificacion de farmacos orales de liberacion retardada a base de hidroxietilcelulosa. |
| US5804413A (en) | 1992-07-31 | 1998-09-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
| GB9415319D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| AU3290397A (en) | 1996-06-10 | 1998-01-07 | Depomed, Inc. | Gastric-retentive oral controlled drug delivery system with enhanced retention properties |
| US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| WO1998055107A1 (en) | 1997-06-06 | 1998-12-10 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| AU8605598A (en) | 1997-07-31 | 1999-02-22 | University Of Pittsburgh | Targeted hsv vectors |
| HK1050135A1 (zh) | 1999-11-02 | 2003-06-13 | Depomed, Inc. | 用於促进将药物给予胃的饭後模式药理学诱导 |
| DE60123384T2 (de) | 2000-02-04 | 2007-08-02 | DepoMed, Inc., Menlo Park | Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert |
| US6488962B1 (en) | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
| US6451808B1 (en) | 2000-10-17 | 2002-09-17 | Depomed, Inc. | Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists |
| MXPA03011096A (es) | 2001-05-29 | 2004-12-06 | Depomed Dev Ltd | Metodo para el tratamiento de la enfermedad de reflujo gastroesofagico y la saturacion acida nocturna. |
| TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| JP2005508358A (ja) | 2001-10-25 | 2005-03-31 | デポメド・インコーポレイテッド | 胃滞留型ロサルタン投与量を用いる治療方法 |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| CA2409552A1 (en) | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| US20030091630A1 (en) | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
| US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
| AU2005302408B2 (en) | 2004-10-28 | 2012-08-09 | The Government of the United States of America as represented by the Department of Veterans Affairs | Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| HRP20100638T2 (hr) | 2006-11-28 | 2011-03-31 | Proyecto De Biomedicina Cima | Viralni vektori i njihova uporaba |
| US8846603B2 (en) | 2010-03-12 | 2014-09-30 | Synageva Biopharma Corp. | NPP1 fusion proteins |
| RU2601154C2 (ru) | 2011-03-11 | 2016-10-27 | Синаджива Байофарма Корп | Гибридные белки npp1 |
| WO2014126965A2 (en) | 2013-02-13 | 2014-08-21 | Yale University | Compositions and methods for treating pathological calcification and ossification |
| ES2523016B1 (es) | 2013-05-20 | 2015-09-09 | 3P Biopharmaceuticals | Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes |
| GB2526339A (en) | 2014-05-21 | 2015-11-25 | Imp Innovations Ltd | Lentiviral vectors |
| EP3194430A1 (en) | 2014-09-16 | 2017-07-26 | Universitat Autònoma De Barcelona | Adeno-associated viral vectors for the gene therapy of metabolic diseases |
| EP3967755B1 (en) * | 2014-12-19 | 2024-03-27 | Inozyme Pharma, Inc. | Soluble npp1 for use in a method for treating pseudoxanthoma elasticum |
| WO2016156468A1 (en) * | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptides |
| EP4414028A3 (en) | 2015-05-19 | 2024-11-27 | Yale University | Compositions for treating pathological calcification conditions, and methods using same |
| EP3303373B1 (en) * | 2015-05-30 | 2020-04-08 | Molecular Templates, Inc. | De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same |
| EP3471747A1 (en) * | 2016-06-16 | 2019-04-24 | Alexion Pharmaceuticals, Inc. | Methods of treating myointimal proliferation |
| CA3032467A1 (en) | 2016-08-05 | 2018-02-08 | Yale University | Compositions and methods for stroke prevention in pediatric sickle cell anemia patients |
| US12134790B2 (en) * | 2017-09-27 | 2024-11-05 | Inozyme Pharma, Inc. | Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1) |
| AU2019267545A1 (en) * | 2018-05-08 | 2020-11-26 | Yale University | Compositions and methods for reducing progression of nephrolithiasis |
| CN120383683A (zh) * | 2018-08-31 | 2025-07-29 | 耶鲁大学 | Enpp1多肽及其使用方法 |
| CA3136118A1 (en) | 2019-04-05 | 2020-10-08 | Yale University | Enpp1 polypeptides and methods of using same |
-
2021
- 2021-06-08 WO PCT/US2021/036494 patent/WO2021252549A1/en not_active Ceased
- 2021-06-08 EP EP21736850.5A patent/EP4162036A1/en active Pending
- 2021-06-08 MX MX2022015772A patent/MX2022015772A/es unknown
- 2021-06-08 CN CN202180059006.4A patent/CN116157145A/zh active Pending
- 2021-06-08 BR BR112022024958A patent/BR112022024958A2/pt unknown
- 2021-06-08 KR KR1020237000507A patent/KR20230042263A/ko active Pending
- 2021-06-08 IL IL298853A patent/IL298853A/en unknown
- 2021-06-08 CA CA3181983A patent/CA3181983A1/en active Pending
- 2021-06-08 AU AU2021286502A patent/AU2021286502A1/en active Pending
- 2021-06-08 JP JP2022575745A patent/JP2023529892A/ja active Pending
- 2021-06-09 AR ARP210101571A patent/AR122578A1/es unknown
- 2021-06-09 TW TW110120998A patent/TW202214849A/zh unknown
-
2022
- 2022-12-08 US US18/063,263 patent/US20230313158A1/en active Pending
-
2023
- 2023-01-03 CO CONC2023/0000016A patent/CO2023000016A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021252549A1 (en) | 2021-12-16 |
| IL298853A (en) | 2023-02-01 |
| AU2021286502A1 (en) | 2023-01-19 |
| AR122578A1 (es) | 2022-09-21 |
| BR112022024958A2 (pt) | 2022-12-27 |
| US20230313158A1 (en) | 2023-10-05 |
| JP2023529892A (ja) | 2023-07-12 |
| CN116157145A (zh) | 2023-05-23 |
| CA3181983A1 (en) | 2021-12-16 |
| KR20230042263A (ko) | 2023-03-28 |
| MX2022015772A (es) | 2023-05-19 |
| EP4162036A1 (en) | 2023-04-12 |
| TW202214849A (zh) | 2022-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20210154B1 (ar) | مثبطات kif18a | |
| BR112023016299A2 (pt) | Composições e métodos para inibir kras | |
| MX2021007104A (es) | Inhibidores de kif18a. | |
| CO2023000016A2 (es) | Proteínas enpp1 o enpp3 solubles y sus usos | |
| MX2021013197A (es) | Cicloalquilos sustituidos como moduladores de la vía integrada del estrés. | |
| EA202092459A1 (ru) | Гибридные белки интерлейкина 12, композиции и способы терапевтического применения, которые их включают | |
| MX2022004345A (es) | Construcciones de igf2 variantes. | |
| EA202092086A1 (ru) | Ингибиторы аргиназы | |
| EA201290209A1 (ru) | Новые модуляторы бензопиран киназы | |
| CO2022003552A2 (es) | Proteínas de fijación multiespecíficas para tratamiento contra el cáncer | |
| IL192282A0 (en) | Compositions and methods for regulating complement system | |
| MX2022000449A (es) | Conjugados peptídicos de citotoxinas como terapéuticos. | |
| EA201071243A1 (ru) | Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом | |
| MX2020009522A (es) | Anticuerpos anti-folato del receptor 1 y usos de los mismos. | |
| MX2020011914A (es) | Anticuerpos anti-dll3 y usos de los mismos. | |
| EA201892225A1 (ru) | АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ | |
| MX2024002989A (es) | Formulaciones de 4-(7-hidroxi-2-isopropil-4-oxo-4h-quinazolin-3-il )-benzonitrilo. | |
| CL2021001209A1 (es) | Constructos de suministro para transcitosis y métodos relacionados | |
| BR112018067946A2 (pt) | formulações tópicas contendo ciclosporina e usos das mesmas | |
| AR101735A1 (es) | Anticuerpo terapéutico anti-bdnf (factor neurotrófico derivado del cerebro) | |
| EA202091205A1 (ru) | Композиции для терапии гипергликемии и сопутствующих состояний | |
| MX2022002437A (es) | Metodos para la produccion de arginasa humana recombinante 1 y sus usos. | |
| BR112021025907A2 (pt) | Método para aumentar o efeito de uma composição de neurotoxina botulínica e composição | |
| CO2019013150A2 (es) | Variantes de proteína morfogénica ósea humana 7 (bmp7) | |
| EA201992626A1 (ru) | Способы и композиции для лечения аллергических заболеваний глаз |